Patents Assigned to Universite de Montpellier
-
Publication number: 20220357326Abstract: A method for quantifying the activity of the proteins/enzymes involved in the conjugation of the SUMO/Ubiquitin/Nedd8 proteins in a cell of a biological sample the method including: a) a step of contacting a cellular extract of cell with each protein of a subgroup of at least 3 proteins wherein the at least 3 proteins corresponds to the proteins essentially including or only including the sequences SEQ ID NO: 1 to 3, b) a step of simultaneously measuring ubiquitination, sumoylation and neddylation level of each of the at least 3 proteins to obtain a first value for ubiquitin, SUMO and Nedd8.Type: ApplicationFiled: May 28, 2020Publication date: November 10, 2022Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIERInventors: Guillaume BOSSIS, Pierre GATEL, Marc PIECHACZYK
-
Publication number: 20220356175Abstract: A compound of formula (Ic) wherein X2 represents a —CO—NRk— group, wherein Rk represents a hydrogen atom or a methyl group, a —NH—CO—NH— group, a —OCH2— group, a —CH(OH)— group, a —NH—CO— group, a —O— group, a —O—(CH2)s—O—, a —CO— group, a —SO2— group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms, —a NH—SO2— or a —SO2—NH— group; Y2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a (C1-C4)alkoxy group, a a group, a group, a morpholinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, a piperidinyl group, or a —CR1R2R3 group, or any of its pharmaceutically acceptable salt.Type: ApplicationFiled: July 9, 2019Publication date: November 10, 2022Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Didier SCHERRER, Jamal TAZI, Florence MAHUTEAU-BETZER, Romain NAJMAN, Julien SANTO, Cécile APOLIT
-
Publication number: 20220348919Abstract: The invention relates to a nucleic acid molecule comprising: a. a first region comprising a nucleic acid sequence coding for the protein Cyclin D1, also called CCND1, said first region being controlled by means allowing the expression of said protein, and b. at least one second region, said second region comprising essentially a sequence from 14 to 59 nucleic acids, said second region corresponding to a transcribed region of a gene, said second region containing at least a genetic modification compared to the same region of the corresponding wild-type version of said gene, said second region being genetically isolated from the means allowing the expression of said protein such that said second region is not translated into a peptide.Type: ApplicationFiled: May 12, 2022Publication date: November 3, 2022Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEInventor: Frederic BIENVENU
-
Patent number: 11478486Abstract: The invention concerns a pharmaceutical combination of an inhibitor of the androgen receptor signaling pathway and of a p38 inhibitor for use in the treatment of prostate cancer in individuals wherein the prostate tumor cells express the AR-V7 variant androgen receptor protein or for preventing the occurrence of resistance in patients suffering from prostate cancer treated by an inhibitor of the androgen receptor signaling pathway. The invention further concerns a pharmaceutical composition comprising enzalutamide, abiraterone or apalutamide and a p38 inhibitor selected from LY2228820 and ARRY-614, and at least one pharmaceutically acceptable excipient.Type: GrantFiled: November 14, 2018Date of Patent: October 25, 2022Assignees: INSTITUT REGIONAL DU CANCER DE MONTPELLIER (ICM), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIERInventors: Céline Gongora, Diego Tosi
-
Extractant for rare earth extraction from aqueous phosphoric acid solutions and method of extraction
Patent number: 11466341Abstract: An extractant which makes it possible to extract both light rare earths and heavy rare earths from an aqueous phosphoric acid solution, likely to be present in this solution, and which is characterised in that it comprises: a compound of formula (I) below: wherein R1 and R2, identical or different, are a hydrocarbon group, saturated or unsaturated, linear or branched, in C6 to C12; R3 is a hydrocarbon group, in C1 to C6, or a hydrocarbon group, saturated or unsaturated, monocyclic, in C3 to C8; R4 and R5, identical or different, are a hydrogen atom or a hydrocarbonate group, saturated or unsaturated, linear or branched, in C2 to C8; and a surfactant. Applications of this extractant include treatment of aqueous solutions from the leaching of natural phosphates by sulphuric acid and aqueous solutions from the leaching of urban minerals by phosphoric acid, in view of making profitable use of the rare earths present in these solutions.Type: GrantFiled: September 14, 2017Date of Patent: October 11, 2022Assignees: COMMISSARIAT Á L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIERInventors: Stéphane Pellet-Rostaing, Julien Rey, Sandrine Dourdain, Guilhem Arrachart, Sefkan Atak -
Publication number: 20220315535Abstract: In vitro or ex vivo methods for screening a quinoline derivative, or anyone of its pharmaceutically acceptable salt, presumed effective in treating and/or preventing an inflammatory disease, the method including: providing an eukaryotic cell, bringing into contact said cell with a quinoline derivative, measuring an expression of miR-124 in the cell, and selecting the candidate presumed effective in treating and/or preventing an inflammatory disease when the level of expression of miR-124 measured is increased relatively to a reference value.Type: ApplicationFiled: May 17, 2022Publication date: October 6, 2022Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Didier SCHERRER, Jamal TAZI
-
Patent number: 11441181Abstract: A use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker, in particular of a viral infection, or of an efficacy of a therapeutic treatment of said viral infection.Type: GrantFiled: January 17, 2014Date of Patent: September 13, 2022Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE, UNIVERSITE DE MONTPELLIER, INSTITUT CURIEInventors: Jamal Tazi, Didier Scherrer, Aude Garcel, Noëlie Campos, Romain Najman, Florence Mahuteau-Betzer
-
Patent number: 11427566Abstract: A compound of formula (I): wherein A and A? independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.Type: GrantFiled: April 15, 2020Date of Patent: August 30, 2022Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Pierre Roux, Florence Mahuteau, Romain Najman, Gilles Gadea, Jamal Tazi, Didier Scherrer, Carsten Brock, Nathalie Cahuzac
-
Publication number: 20220267522Abstract: The present invention relates to new biopolymer, i.e. bioorganic nylons incorporating peptidic blocks obtained by a process of polymerization of amino peptidic blocks. The process of the invention comprises the steps of mixing amino peptidic blocks with or without a diaminoalcane and reacting the mixture according to polycondensation with a diacyl chloride in homogeneous or heterogeneous media.Type: ApplicationFiled: March 8, 2022Publication date: August 25, 2022Applicants: Universite De Montpellier, Centre National de la Recherche Scientifique (CNRS)Inventors: Jean Martinez, Ahmad Mehdi, Gilles Subra, Saïd Jebors
-
Publication number: 20220240942Abstract: The invention relates to an intra-aneurysm device (1) for treating an aneurysm (2), comprising a woven structure (S), with meshes made of a plurality of yarns, the woven structure (S) comprising a head (5) intended to be inserted into the aneurysm (2), the head (5) being capable of significantly reducing a blood flow in the aneurysm (2), said head (5) being dome-shaped, the device (1) being characterised in that the woven structure (S) comprises, at a proximal end of said woven structure (S) a knot (4a) connected to the head (5) and in that, at its distal end opposite the proximal end, the head (5) is formed from yarn ends (6a), at least some of which are mechanically connected one another.Type: ApplicationFiled: July 29, 2020Publication date: August 4, 2022Applicants: Universite de Montpellier, Centre Hospitalier Universitaire de Montpellier, Centre National de la Recherche ScientifiqueInventors: Lionel Bichet, Hervé Louche, Franck Jourdan, Vincent Costalat
-
Patent number: 11396532Abstract: The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains can-y one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.Type: GrantFiled: May 4, 2020Date of Patent: July 26, 2022Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIERInventors: Jan Tavernier, Jennyfer Bultinck, Frank Peelman, Gilles Uze
-
Patent number: 11390643Abstract: The present invention relates to a modified oligonucleotide having two or more thiol functions, which can be immobilized on a gold surface or on a grafted surface, in particular a surface comprising at least one carbon-carbon double bond or carbon-carbon triple bond or haloacetamide functions, preferably maleimide or acrylamide functions. The invention also relates to a method for detecting a nucleic acid in a biological sample comprising a step of detecting hybridization between a modified oligonucleotide and a target nucleic acid amplified from the biological sample. The invention relates more particularly to a method for detecting, genotyping or sequencing a pathogenic organism, preferably a virus.Type: GrantFiled: February 8, 2019Date of Patent: July 19, 2022Assignees: ETABLISSEMENT FRANÇAIS DU SANG, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE MONTPELLIER, UNIVERSITE CLAUDE BERNARD LYON 1Inventors: Chantal Fournier-Wirth, Myriam Lereau, Jean-François Cantaloube, Jean-Jacques Vasseur, François Morvan, Albert Meyer, Julie Mayen, Carole Chaix, Carole Farre
-
Publication number: 20220196538Abstract: A device for medical analyses with cellular impedance signal processing comprises a memory (4) arranged to receive pulse data sets, each pulse data set comprising impedance value data that are associated each time with a time marker, these data together representing a curve of cellular impedance values that are measured as a cell passes through a polarized opening, a computer (6) arranged to process a pulse data set by determining a rotation value indicating whether the cell from which this pulse data set has been taken has undergone a rotation during its passage through the polarized opening, and a classifier (8) arranged to retrieve from the computer (6) a given pulse data set, and to use the resulting rotation value to classify the given pulse data set in a rotation pulse data set group (10) or a rotationless pulse data set group (12).Type: ApplicationFiled: April 24, 2020Publication date: June 23, 2022Applicants: HORIBA ABX SAS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S), UNIVERSITE DE MONTPELLIERInventors: Pierre TARACONAT, Damien ISEBE, Simon MENDEZ, Franck NlCOUD
-
Patent number: 11358997Abstract: The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.Type: GrantFiled: August 14, 2018Date of Patent: June 14, 2022Assignees: VIB VZW, Universiteit Gent, Centre National De La Recherche Scientifique, Université De Montpellier, Centre Hospitalier Regional Universitaire de MontpellierInventors: Jan Tavernier, Jennyfer Bultinck, Sarah Gerlo, Gilles Uze, Franciane Paul, Yann Bordat
-
Patent number: 11339191Abstract: The present invention relates to peptidomimetic macrocycles comprising at least one macrocycle-forming linker and an amino acid sequence chosen from the group consisting of: i) an amino acid sequence with at least about 50%, 60%, 70%, 80%, 90%, or 95% sequence identity to a human sequence IRAK2 54-71 (SEQ ID No1) and 100% identity with the amino acids in the positions 5-6, 9-11, 14-15 or ii) an amino acid sequence with at least about 50%, 60%, 70, 80%, 90%, or 95% sequence identity to a human sequence IRAKM 66-83 (SEQ ID No2) and 100% identity with the amino acids in the positions 5-6, 9-11, 13-14, wherein the peptidomimetic macrocycle comprises an a-helix and at least two natural or two non-natural amino acids crosslinked by a macrocycle-forming linker. It also concerns method of preparation of said peptidomimetic macrocycles and uses thereof, pharmaceutical composition and uses thereof, in particular as inhibitors of inflammatory pathways.Type: GrantFiled: December 22, 2017Date of Patent: May 24, 2022Assignees: Universite de Montpellier, Centre National de la Recherche Scientifique (CNRS)Inventors: Guillaume Laconde, Muriel Amblard-Caussil, Jean Martinez, Christian Jorgensen, Florence Apparailly-Sechan, Isabelle Duroux-Richard
-
IN VITRO METHOD FOR ASSESSING THE RISK OF PROSTATE SIDE EFFECT AFTER TREATMENT BY IONIZING RADIATION
Publication number: 20220157462Abstract: The present invention relates to an in vitro method for assessing the risk of developing side effects after ionizing radiation treatment in a prostate cancer subject, comprising the steps of a)determining the presence or absence of urinary toxicity in the patient prior to application of ionizing radiation, b)determining the stage of the tumor, c)optionally determining of at least one other clinical parameter, disease parameter or ionizing radiation treatment parameter from the patient, and d)combining a value associated with the presence of urinary toxicity determined in a), a value associated with the stage of the tumor in b), and a value association with the at least one other clinical parameter, disease parameter or ionizing radiation treatment parameter determined in c) in a mathematical function to obtain an end-valueType: ApplicationFiled: March 5, 2020Publication date: May 19, 2022Applicants: Novagray, Institut Régional du Cancer de Montpellier, Université de MontpellierInventors: Clémence FRANC, David Azria, Sophie Gourgou -
Publication number: 20220145406Abstract: Biomarkers and uses thereof in monitoring, assessing, and/or treatment of viral infections, or inflammatory diseases, disorders, or conditions, or cancer.Type: ApplicationFiled: December 19, 2019Publication date: May 12, 2022Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITÉ DE MONTPELLIERInventors: Philippe POULETTY, Hartmut EHRLICH, Didier SCHERRER, Jamal TAZI, Laurent MANCHON
-
IN VITRO METHOD FOR ASSESSING THE RISK OF PROSTATE SIDE EFFECT AFTER TREATMENT BY IONIZING RADIATION
Publication number: 20220137030Abstract: The present invention relates to an in vitro method for assessing the risk of developing side effects after ionizing radiation treatment in a prostate cancer subject, comprising the steps of a) measuring radiation induced T-lymphocytes apoptosis in a sample of the subject; b) determining the presence of urinary toxicity in the patient prior to application of ionizing radiation, and optionally of at least one other clinical parameter, disease parameter or ionizing radiation treatment parameter from the patient, and c) combining the value of the at least one biochemical marker measured in step (a) and a value associated with the at least one clinical parameter, disease parameter or ionizing radiation treatment parameter determined in step (b) in a mathematical function to obtain an end-value.Type: ApplicationFiled: March 5, 2020Publication date: May 5, 2022Applicants: Institut Régional du Cancer de Montpellier, Université de MontpellierInventors: David Azria, Sophie Gourgou -
Publication number: 20220133392Abstract: The present invention relates to a microfluidic chip for attracting and destroying a specific biological element, said chip comprising: a reservoir (1) consisting of a matrix comprising a chemoattractant compound capable of attracting the biological element at least one network of microchannels (2) arranged between the reservoir (1) and the external environment (3) of the chip and allowing the chemoattractant compound to pass to said environment and the biological element present in said environment to pass to the reservoir (1) at least one electrode (4) arranged between the reservoir (1) and the network of microchannels (2) or at the same location as the network of microchannels (2), said electrode (4) being capable of generating an electric field so as to destroy the biological element during its passage to the reservoir (1).Type: ApplicationFiled: March 12, 2020Publication date: May 5, 2022Applicants: UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIERInventors: Benoît CHARLOT, Jean-Marie RAMIREZ, Sébastien MEANCE, Xavier GARRIC, Coline PINESE, Isabelle GUIRAUD
-
Publication number: 20220127253Abstract: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3) alkyl group.Type: ApplicationFiled: May 21, 2021Publication date: April 28, 2022Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIERInventors: Jamal TAZI, Florence MAHUTEAU, Pierre ROUX, Romain NAJMAN, Didier SCHERRER, Carsten BROCK, Nathalie CAHUZAC, Gilles GADEA, Noelie CAMPOS, Aude GARCEL, Julien SANTO